Translating research to remedies...
The Swiss Cancer Center (SCC) fosters innovation by integrating translational and clinical cancer research. It leads cutting-edge basic and translational cancer research in personalized molecular therapies and immunotherapy with the aim of developing outstanding multidisciplinary care for cancer patients.
The SCC creates integrated multidisciplinary laboratory spaces, bringing together CHUV, EPFL ISREC, Ludwig and UNIL scientific groups and external collaborators with the common focus and diverse expertise to solve specific cancer problems.
Bioengineers, immune engineers, bioinformaticians, chemists,molecular biologists, mouse modelists, cancer biologists, imaging experts, cancer therapy investigators and clinician- scientists work in the same environment, to maximize interactions. Groups focus on specific cancer types but also on specific therapy questions, for example drug development or immune engineering.
The combined environments of all of the founding members and our partners offer unique and complementary strengths leading to unparalleled opportunities for discovery and therapeutic development.
In January 2013, the CHUV, UNIL, EPFL and the ISREC Foundation unveiled their partnership plans for the creation of the Swiss Cancer Center (SCC). A letter of intent signed by these institutions, set out a common vision for cutting-edge cancer research.
In 2015, Ludwig Cancer Research opened a new Branch in Lausanne, thus deepening its research presence in Switzerland. The Ludwig Lausanne Branch is based at the University of Lausanne (UNIL) and the Lausanne University Hospital (CHUV), and operates in close collaboration with the new Swiss Cancer Center Lausanne. The Branch will also receive support from the Canton of Vaud. Strong partnerships are also evolving with the University of Geneva and its hospitals (HUG), as well as with clinical colleagues in the Western region of Switzerland -through the current development of the regional Réseau suisse-romand d’oncologie.
The SCC is thus a truly integrated research community whose multidisciplinary cancer research programs all have a common focus, that of engaging in the search for solutions in the fight against cancer, and offering the most innovative approaches to cancer patients, in order to significantly improve longevity and quality of life.
The combined strengths and complementary environments of the founding institutions and its partners are central to the creation of unparalleled opportunities for discovery and clinical development. Interaction and collaboration between clinicians, researchers and bioengineers will allow synergy between cutting-edge basic, translational and clinical cancer research and facilitate direct translation of science to the clinic.
At the heart of the Western Switzerland’s Health Valley, home to 450 biotechs, 300 medtech companies, 500 biomedical research laboratories and 8 incubators, the SCC will be a catalyst in fostering innovation in cancer medicine in the BioAlps network, the Life Science cluster of Western Switzerland.